Factors influencing long-term outcomes following renal transplantation: A review

Journal of the Nepal Medical Association

Volumn 46, Issue 167, 2007, Pages 136-142

  Shrestha, B M ^a   Haylor, J L ^a  

^a Sheffield Kidney Institute   (United Kingdom)

Author keywords

Calcineurin inhibitors; Chronic allograft nephropathy; Long term outcomes; Renal transplantation

Indexed keywords

ALEMTUZUMAB; AMINOGLYCOSIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CONTRAST MEDIUM; CYCLOSPORIN A; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; FINGOLIMOD; HLA ANTIBODY; HUMORAL ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 3; QUINOLONE DERIVATIVE; RAPAMYCIN; RITUXIMAB; STEROID; SULFONAMIDE; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS DNA;

ACUTE GRAFT REJECTION; ANTIGEN ANTIBODY REACTION; BK VIRUS; BLOOD PRESSURE REGULATION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DETERIORATION; DIABETES MELLITUS; DRUG SUBSTITUTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMOLYTIC UREMIC SYNDROME; HLA MATCHING; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDICAL PRACTICE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PLASMAPHERESIS; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; REVIEW; SIDE EFFECT; SURVIVAL TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS DIAGNOSIS; VIRUS REACTIVATION;

EID: 42249109398     PISSN: 00282715     EISSN: None     Source Type: Journal    
DOI: 10.31729/jnma.290     Document Type: Review

References (80)

1. Wolfe RA, Ashby VB, Milford EL. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341(23):1725-30.
2. Calne R. Clinical transplantation: current problems, possible solutions. Philos Trans R Soc Lond B Biol Sci 2005; 360(1461):1797-801.
3. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999; 56(3):783-93.
4. Hariharan S, Johnson CP, Bresnahan BA. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342(9):605-12.
5. Gjertson DW, Cecka JM. Living unrelated donor kidney transplantation. Kidney Int 2000; 58(2):491-9.
6. Koo DD, Welsh KI, McLaren AJ. Cadaver versus living donor kidneys: impact of donor factors on antigen induction before transplantation. Kidney Int 1999; 56(4):1551-9.
7. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10(1):167-81.
8. Bunnapradist S, Gritsch HA, Peng A. Dual kidneys from marginal adult donors as a source for cadaveric renal transplantation in the United States. J Am Soc Nephrol 2003; 14(4):1031-6.
9. Fritsche L, Horstrup J, Budde K. Old-for-old kidney allocation allows successful expansion of the donor and recipient pool. Am J Transplant 2003; 3(11):1434-9.
10. Kwon OJ, Kwak JY, Kang CM. The impact of gender and age matching for long-term graft survival in living donor renal transplantation. Transplant Proc 2005; 37(2):726-8.
11. Opelz G, Wujciak T, Dohler B. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999; 1(3):334-42.
12. Sijpkens YW, Doxiadis, II, Mallat MJ. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003; 75(2):204-8.
13. Wujciak T, Opelz G. Evaluation of HLA matching for CREG antigens in Europe. Transplantation 1999; 68(8):1097-9.
14. Raiz LR, Kilty KM, Henry ML, Ferguson RM. Medication compliance following renal transplantation. Transplantation 1999; 68(1):51-5.
15. Segoloni GP, Messina M, Giraudi R. Renal transplantation in patients over 65 years of age: no more a contraindication but a growing indication. Transplant Proc 2005; 37(2):721-5.
16. Cecka JM. The OPTN/UNOS Renal Transplant Registry 2003. Clin Transpl 2003:1-12.
17. Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344(10):726-31.
18. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74(10):1377-81.
19. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69(3):319-26.
20. Akalin E, Dinavahi R, Dikman S. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol 2007; 2(6):1261-7.
21. Sola R, Alarcon A, Jimenez C, Osuna A. The influence of delayed graft function. Nephrol Dial Transplant 2004; 19 Suppl 3:32-7.
22. Lebranchu Y, Halimi JM, Bock A. Delayed graft function: risk factors, consequences and parameters affecting outcome-results from MOST, A Multinational Observational Study. Transplant Proc 2005; 37(1):345-7.
23. Keith DS, DeMattos A, Golconda M. Factors associated with improvement in deceased donor renal allograft function in the 1990s. J Am Soc Nephrol 2005; 16(5):1512-21.
24. Steinmetz OM, Lange-Husken F, Turner JE. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 2007; 84(7):842-50.
25. Racusen LC, Solez K, Colvin RB. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55(2):713-23.
26. Shah A, Nadasdy T, Arend L. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004; 77(9):1399-405.
27. Lehrich RW, Rocha PN, Reinsmoen N. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Hum Immunol 2005; 66(4):350-8.
28. Shrestha BM, Parton D, Gray A. Cytomegalovirus involving gastrointestinal tract in renal transplant recipients. Clin Transplant 1996; 10(2):170-5.
29. Drachenberg CB, Beskow CO, Cangro CB. Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. Hum Pathol 1999; 30(8):970-7.
30. Williams JW, Javaid B, Kadambi PV. Leflunomide for Polyomavirus type BK nephropathy. N Engl J Med 2005; 352(11):1157-8.
31. Reischig T, Jindra P, Mares J. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 2005; 79(3):317-24.
32. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4(6):928-36.
33. Ahmed J, Velarde C, Ramos M. Outcome of low-dose ganciclovir for cytomegalovirus disease prophylaxis in renal-transplant recipients. Transplantation 2004; 78(11):1689-92.
34. Cantarovich D, Vistoli F, Soulillou JP. Immunosuppression minimization in kidney transplantation. Front Biosci 2008; 13:1413-32.
35. Takeda A, Uchida K, Haba T. Chronic cyclosporin nephropathy: long-term effects of cyclosporin on renal allografts. Clin Transplant 2001; 15 Suppl 5:22-9.
36. Weir MR. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation. Transplant Proc 2001; 33(4 Suppl):19S-28S.
37. Ostrowska J, Pazik J, Lewandowski Z. Posttransplantation glomerulonephritis: risk factors associated with kidney allograft loss. Transplant Proc 2007; 39(9):2751-3.
38. Briganti EM, Russ GR, McNeil JJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347(2):103-9.
39. Ponticelli C, Campise M, Tarantino A. The different patterns of response to plasmapheresis of recurrent focal and segmental glomerulosclerosis. Transplant Proc 2002; 34(8):3069-71.
40. Schwarz A, Krause PH, Offermann G, Keller F. Recurrent and de novo renal disease after kidney transplantation with or without cyclosporine A. Am J Kidney Dis 1991; 17(5):524-31.
41. Schwimmer J, Nadasdy TA, Spitalnik PF. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41(2):471-9.
42. Schiel R, Heinrich S, Steiner T. Post-transplant diabetes mellitus: risk factors, frequency of transplant rejections, and long-term prognosis. Clin Exp Nephrol 2005; 9(2):164-9.
43. Kasiske BL, Anjum S, Shah R. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43(6):1071-81.
44. Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5(11):2725-31.
45. Kandzari DE, Rebeiz AG, Wang A, Sketch MH, Jr. Contrast nephropathy : an evidence-based approach to prevention. Am J Cardiovasc Drugs 2003; 3(6):395-405.
46. Butler JA, Peveler RC, Roderick P. Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation 2004; 77(5):786-9.
47. Merion RM, White DJ, Thiru S. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984; 310(3):148-54.
48. Kahan BD, Mickey R, Flechner SM. Multivariate analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. Transplantation 1987; 43(1):65-70.
49. Curtis JJ, Lynn M, Jones PA. Neoral conversion from Sandimmune in maintenance renal transplant patients: an individualized approach. J Am Soc Nephrol 1998; 9(7):1293-300.
50. Mayer AD, Dmitrewski J, Squifflet JP. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64(3):436-43.
51. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359(9308):741-6.
52. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65(11):1450-4.
53. David KM, Morris JA, Steffen BJ. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 2005; 19(2):279-85.
54. Kahan BD, Julian BA, Pescovitz MD. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999; 68(10):1526-32.
55. Parrott NR, Hammad AQ, Watson CJ. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients. Transplantation 2005; 79(3):344-8.
56. Morris JA, Hanson JE, Steffen BJ. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clin Transplant 2005; 19(3):340-5.
57. Webster AC, Woodroffe RC, Taylor RS. Tacrolimus versus Ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. Bmj 2005; 331(7520):810.
58. Nashan B, Bock A, Bosmans JL. Use of Neoral C monitoring: a European consensus. Transpl Int 2005; 18(7):768-78.
59. Goggins WC, Pascual MA, Powelson JA. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76(5):798-802.
60. Thistlethwaite JR, Jr., Heffron TG, Stuart JK. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients. Am J Kidney Dis 1989; 14(5 Suppl 2):28-34.
61. Bunnapradist S, Hong A, Lee B, Takemoto SK. Multivariate analysis of the effectiveness of using antibody induction therapy according to the degree of HLA mismatches. Transplant Proc 2005; 37(2):886-8.
62. Velosa JA, Larson TS, Gloor JM, Stegall MD. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. Am J Kidney Dis 2001; 38(4 Suppl 2):S3-S10.
63. Augustine JJ, Hricik DE. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 2006; 1(5):1080-9.
64. Rama I, Cruzado JM, Gil-Vernet S. Steroids can be safely withdrawn from cyclosporine and mycophenolate mofetil-treated renal allograft recipients: long-term results. Transplantation 2005; 80(2):164-8.
65. Pascual J, Mareen R, Ortuno J. Clinical experience with everolimus (Certican): optimizing dose and tolerability. Transplantation 2005; 79(9 Suppl):S80-4.
66. Massari P, Duro-Garcia V, Giron F. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 2005; 37(2):916-9.
67. Watson CJ, Bradley JA, Friend PJ. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005; 5(6):1347-53.
68. Knechtle SJ, Fernandez LA, Pirsch JD. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004; 136(4):754-60.
69. Tedesco-Silva H, Mourad G, Kahan BD. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005; 79(11):1553-60.
70. Delbridge MS, Shrestha BM, Raftery AT. Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine. Transplantation 2007; 84(2):187-95.
71. Sijpkens YW, Doxiadis, II, van Kemenade FJ. Chronic rejection with or without transplant vasculopathy. Clin Transplant 2003; 17(3):163-70.
72. Montagnino G, Banfi G, Campise MR. Impact of chronic allograft nephropathy and subsequent modifications of immunosuppressive therapy on late graft outcomes in renal transplantation. Nephrol Dial Transplant 2004; 19(10):2622-9.
73. Dudley C, Pohanka E, Riad H. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79(4):466-75.
74. Tang SC, Chan KW, Tang CS. Conversion of Ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy. Nephrol Dial Transplant 2006; 21(11):3243-51.
75. Bumbea V, Kamar N, Ribes D. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20(11):2517-23.
76. Premasathian NC, Muehrer R, Brazy PC. Blood pressure control in kidney transplantation: therapeutic implications. J Hum Hypertens 2004; 18(12):871-7.
77. Ramanathan V, Suki WN, Rosen D, Truong LD. Chronic allograft nephropathy and nephrotic range proteinuria. Clin Transplant 2005; 19(3):413-7.
78. Holdaas H. Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy? Am J Cardiovasc Drugs 2005; 5(4):255-69.
79. Zaltzman JS, Nash M, Chiu R, Prasad R. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 2004; 19(4):940-4.
80. Halimi JM, Giraudeau B, Buchler M. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant 2007; 21(2):277-84.